Screener / SEC EDGAR /CIK 0001579428 /10-K filed Feb 23, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Axsome Therapeutics, Inc. AXSM

We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. 10-K, Item 1

Headquarters
New York, NY
CEO
Herriot Tabuteau
Next results
around Jan 11, 2027
Compare with peers Embed

AXSM among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 65.5%, above 94% of 154 peers (their median 10.4%) REVENUE GROWTH 65.5% · above 94% Operating margin: -17.5%, above 18% of 138 peers (their median 10.2%) OPERATING MARGIN -17.5% · above 18% Net margin: -18.2%, above 18% of 153 peers (their median 6.8%) NET MARGIN -18.2% · above 18% FCF margin: -9.5%, above 16% of 144 peers (their median 10.1%) FCF MARGIN -9.5% · above 16%
AXSM Peer median Below the median

What changed

22 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 23, 2026 against Feb 18, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Inventory growing faster than revenue
    Inventory +77.6% ($15.7M to $27.9M) vs revenue +65.5% ($385.7M to $638.5M), +12.0 pts apart
  • Receivables +58.1% ($142.0M to $224.5M) vs revenue +65.5% ($385.7M to $638.5M), -7.5 pts apart
9 more checks with nothing to note
  • Cash from operations −$93.4M vs net income −$183.2M (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: Deloitte & Touche LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Reserves for Variable Consideration - Commercial Managed Care
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

22 paragraphs in Risk Factors that were not in the 10-K filed Feb 18, 2025. Quoted as filed.

All 22 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    On May 8, 2025 (the “Closing Date”), we entered into a loan agreement (the “Blackstone Loan Agreement”) with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”), certain subsidiaries party thereto as guarantors,…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    General political uncertainty may have an adverse impact on our operating performance and results of operations. In particular, the U.S. continues to experience significant political events that cast uncertainty on the U.S. and global financial and economic markets. For example, on October 1, 2025, the U.S. federal government commenced…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    Further, the FDA’s review of our regulatory submissions may be delayed in the future due to reasons beyond our control. FDA operations are affected by various factors, such as shifting government priorities, budgets and funding levels, authorization and payment of user fees, the ability to hire and retain key personnel, as well as other…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    For example, in early September 2025, following a presidential memorandum directing the FDA to “take appropriate action to enforce the Federal Food, Drug, and Cosmetic Act’s prescription drug advertising provisions, and otherwise ensure truthful and non-misleading information in direct-to-consumer (DTC) prescription drug…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$50.0M$270.6M$385.7M$638.5M
Net income−$187.1M−$239.2M−$287.2M−$183.2M
Operating cash flow−$116.5M−$145.1M−$128.4M−$93.4M
Free cash flow−$117.2M−$145.7M−$128.7M−$93.9M

Revenue, FY2020 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$638.5M ▲ 65.5% in FY2025

FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Axsome Therapeutics, Inc., New York, NY · from the 10-K filed Feb 23, 2026

We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes. Our innovative CNS portfolio is anchored by three U.S.

Headquarters
New York, NY
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 2, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AXSM/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.